Viking Therapeutics Inc (VKTX) Expected to Post Earnings of -$0.10 Per Share

Equities analysts forecast that Viking Therapeutics Inc (NASDAQ:VKTX) will post earnings per share (EPS) of ($0.10) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Viking Therapeutics’ earnings. The lowest EPS estimate is ($0.12) and the highest is ($0.09). Viking Therapeutics reported earnings per share of ($0.14) in the same quarter last year, which suggests a positive year-over-year growth rate of 28.6%. The company is expected to issue its next earnings results on Wednesday, March 6th.

On average, analysts expect that Viking Therapeutics will report full-year earnings of ($0.43) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.40). For the next year, analysts anticipate that the firm will post earnings of ($0.46) per share, with EPS estimates ranging from ($0.55) to ($0.34). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Viking Therapeutics.

Several research firms have recently weighed in on VKTX. Maxim Group reiterated a “buy” rating and set a $28.00 price objective on shares of Viking Therapeutics in a research report on Thursday, November 8th. Raymond James upgraded shares of Viking Therapeutics from an “outperform” rating to a “strong-buy” rating and set a $43.00 price objective for the company in a report on Monday, November 19th. They noted that the move was a valuation call. B. Riley initiated coverage on shares of Viking Therapeutics in a research report on Tuesday, December 11th. They set a “buy” rating and a $16.00 price target on the stock. BidaskClub raised shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 2nd. Finally, HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Viking Therapeutics in a research note on Thursday, November 8th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $26.29.

A number of hedge funds and other institutional investors have recently modified their holdings of VKTX. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Viking Therapeutics in the 4th quarter worth $30,000. Lindbrook Capital LLC purchased a new stake in shares of Viking Therapeutics in the 4th quarter worth about $36,000. Great West Life Assurance Co. Can purchased a new stake in shares of Viking Therapeutics in the 4th quarter worth about $53,000. Meeder Asset Management Inc. grew its position in shares of Viking Therapeutics by 63.5% in the 4th quarter. Meeder Asset Management Inc. now owns 7,309 shares of the biotechnology company’s stock worth $56,000 after buying an additional 2,839 shares during the period. Finally, Nisa Investment Advisors LLC purchased a new stake in shares of Viking Therapeutics in the 4th quarter worth about $60,000. Institutional investors and hedge funds own 60.23% of the company’s stock.

Shares of NASDAQ VKTX traded down $0.24 during trading hours on Friday, hitting $8.73. 83,716 shares of the stock were exchanged, compared to its average volume of 2,741,031. The firm has a market capitalization of $570.25 million, a price-to-earnings ratio of -11.06 and a beta of 2.76. Viking Therapeutics has a 1-year low of $3.69 and a 1-year high of $24.00.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

See Also: Dividend Aristocrat Index

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit